2243227-60-1
2243227-60-1 structure
- Name: KWAR 23
- Chemical Name: KWAR 23
- CAS Number: 2243227-60-1
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2022-10-11 06:18:48
- Modify Date: 2024-01-12 18:39:25
-
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research[1].
| Name | KWAR 23 |
|---|
| Description | KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | KWAR 23 (0-1 μM; 4 h) shows antitumor activity of human neutrophil and macrophage[1]. KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines[1]. Cell Viability Assay[1] Cell Line: Human macrophages and lymphoma cells Concentration: 0-1 μM Incubation Time: 4 h Result: Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23. |
| In Vivo | KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model[1]. KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice[1]. Animal Model: SIRPA knock-in mouse model injected with Burkitt’s lymphoma cells[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg; every other day; 21 d Result: Led to strong inhibition of tumor growth when combined with Rituximab. |
| References |
| No Any Chemical & Physical Properties |